Alector to Participate in Upcoming Healthcare Conferences
Alector Reports Fourth Quarter and Full Year 2023 Financial Results
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Alector Announces Closing of Public Offering
Alector Announces Pricing of Public Offering of Common Stock
Alector Announces Proposed Public Offering of Common Stock
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation